Recursion Pharmaceuticals (RXRX) Sees a More Significant Dip Than Broader Market: Some Facts to Know

Recursion Pharmaceuticals (RXRX) reached $3.44 at the closing of the latest trading day, reflecting a -1.99% change compared to its last close.

Zacks Investment Research • Mar 10, 2026

Can This AI Stock Bounce Back in 2026?

Recursion Pharmaceuticals is looking to use AI to speed up R&D in the biotech industry. The company has yet to show the value of its approach and faces significant uncertainty.

The Motley Fool • Mar 8, 2026

Recursion Pharmaceuticals, Inc. (RXRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Presents at TD Cowen 46th Annual Health Care Conference Transcript

Seeking Alpha • Mar 6, 2026

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript

Recursion Pharmaceuticals, Inc. (RXRX) Q4 2025 Earnings Call Transcript

Seeking Alpha • Feb 25, 2026

Recursion Reports Fourth Quarter and Full Year 2025 Financial Results and Provides Business Update

SALT LAKE CITY, Feb. 25, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX) a leading clinical stage TechBio company decoding biology to radically improve lives, today reported business updates and financial results for its fourth quarter and full year ending December 31, 2025.

GlobeNewsWire • Feb 25, 2026

RXRX Q4 Loss Narrower Than Expected, Revenues Increase Y/Y, Stock Up

Recursion Pharmaceuticals stock up on narrower Q4 loss as revenues jump on Roche milestone, beating estimates and boosting cash runway into 2028.

Zacks Investment Research • Feb 25, 2026

Recursion Pharmaceuticals (RXRX) Reports Q4 Loss, Beats Revenue Estimates

Recursion Pharmaceuticals (RXRX) came out with a quarterly loss of $0.21 per share versus the Zacks Consensus Estimate of a loss of $0.28. This compares to a loss of $0.53 per share a year ago.

Zacks Investment Research • Feb 25, 2026

Recursion To Be Featured in HighRes' Lightning Talk at NVIDIA GTC

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today it will be featured in HighRes' Lightning Talk at the NVIDIA GTC AI Conference & Expo happening March 16-19 in San Jose. Moderated by Stacie Calad-Thomson, Business Development Lead for Healthcare and Life Sciences at NVIDIA, the talk, “AI Agents, Robotics, and Digital Twins: The Full Stack of Self-Driving Labs and Biomanufacturing,” will showcase how AI, automation, and robotics are driving the new era of drug discovery and development.

GlobeNewsWire • Feb 23, 2026

Recursion to Participate in Upcoming Investor Conferences

Salt Lake City, Feb. 23, 2026 (GLOBE NEWSWIRE) -- Recursion (Nasdaq: RXRX), a leading clinical stage TechBio company decoding biology to radically improve lives, announced today its participation in the following upcoming investor conferences: TD Cowen 46th Annual Healthcare Conference - Monday, March 2, 2026 Leerink Partners 2026 Global Healthcare Conference - Monday, March 9, 2026 Jefferies 2026 Biotech on the Beach Summit — Wednesday, March 11, 2026 KeyBanc 2026 Healthcare Forum — Tuesday, March 17, 2026 Webcasts may be found in the events section of the Recursion Investor Relations website at ir.recursion.com . About Recursion Recursion (NASDAQ: RXRX) is a clinical stage TechBio company leading the space by decoding biology to radically improve lives.

GlobeNewsWire • Feb 23, 2026

What's in Store for These 5 Medical Companies This Earnings Season?

IRWD, RXRX, NVAX, VTRS and NTLA gear up for earnings as the Medical sector posts solid sales growth despite a slight profit dip so far.

Zacks Investment Research • Feb 23, 2026